Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with …

この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with …
この記事を読む
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies. Satoh…
この記事を読む
The tyranny of non-inferiority trials. Tannock IF et al.Lancet Oncol.2024 Oct;25(10):e520-e525.PMID:39362263. Abs of abs…
この記事を読む
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations. Shahnam A et al…
この記事を読む
Risk Factors for Locoregional Relapse After Segmentectomy:Supplementary Analysis of the JCOG0802/WJOG4607L Trial. Nakaga…
この記事を読む
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population. Bak M et al.J Thorac Oncol.…
この記事を読む
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. Saal J …
この記事を読む
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database…
この記事を読む
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc …
この記事を読む
Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Dire…